The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities

Li H(2014)Dimethyl Sulfoxide Suppresses Mouse 4T1 Breast Cancer Growth by Modulating Tumor-Associated Macrophage Differentiation J. Breast Cancer 17 577-1313

Chouaib S(2015)M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide BMC Cancer 15 450-483

Ren G(2010)Clinical development of the anti-CTLA-4 antibody tremelimumab Semin. Oncol. 37 420-e307

Gan L(2004)Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 Nat Rev Immunol 4 39-undefined

Qiu Z(2018)The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy Blood 131 1027-undefined

Huang J(2016)From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway Drug Discovery Today 21 141-undefined

Li Y(2017)Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer Pathology 49 304-undefined

Huang H(2018)Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma Int. J. Clin. Exp. Pathol. 11 122-undefined

Xiang T(2018)Checkpoint inhibitors in breast cancer - Current status Cancer Treat Rev 63 4-undefined

Wan J(2018)Checkpoint blockade in the treatment of breast cancer: current status and future directions Br. J. Cancer 119 7189-undefined

Li H(2014)Dimethyl Sulfoxide Suppresses Mouse 4T1 Breast Cancer Growth by Modulating Tumor-Associated Macrophage Differentiation J. Breast Cancer 17 577-1313

Chouaib S(2015)M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide BMC Cancer 15 450-483

Ren G(2010)Clinical development of the anti-CTLA-4 antibody tremelimumab Semin. Oncol. 37 420-e307

Gan L(2004)Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 Nat Rev Immunol 4 39-undefined

Qiu Z(2018)The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy Blood 131 1027-undefined

Huang J(2016)From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway Drug Discovery Today 21 141-undefined

Li Y(2017)Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer Pathology 49 304-undefined

Huang H(2018)Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma Int. J. Clin. Exp. Pathol. 11 122-undefined

Xiang T(2018)Checkpoint inhibitors in breast cancer - Current status Cancer Treat Rev 63 4-undefined

Wan J(2018)Checkpoint blockade in the treatment of breast cancer: current status and future directions Br. J. Cancer 119 7189-undefined